Genetic Diversity and Natural Selection of Plasmodium Vivax Reticulocyte Invasion Genes in Ecuador

Overview

Journal Malar J

Publisher Biomed Central

Specialty Tropical Medicine

Date 2023 Aug 3

PMID 37537581

Authors

Andres Nunez

Francis B Ntumngia

Yasel Guerra

John H Adams

Fabian E Saenz

Affiliations

Soon will be listed here.

Abstract

Background: Knowledge of the diversity of invasion ligands in malaria parasites in endemic regions is essential to understand how natural selection influences genetic diversity of these ligands and their feasibility as possible targets for future vaccine development. In this study the diversity of four genes for merozoite invasion ligands was studied in Ecuadorian isolates of Plasmodium vivax.

Methods: Eighty-eight samples from P. vivax infected individuals from the Coast and Amazon region of Ecuador were obtained between 2012 and 2015. The merozoite invasion genes pvmsp-1-19, pvdbpII, pvrbp1a-2 and pvama1 were amplified, sequenced, and compared to the Sal-1 strain. Polymorphisms were mapped and genetic relationships between haplotypes were determined.

Results: Only one nonsynonymous polymorphism was detected in pvmsp-1-19, while 44 nonsynonymous polymorphisms were detected in pvdbpII, 56 in pvrbp1a-2 and 33 in pvama1. While haplotypes appeared to be more related within each area of study and there was less relationship between parasites of the coastal and Amazon regions of the country, diversification processes were observed in the two Amazon regions. The highest haplotypic diversity for most genes occurred in the East Amazon of the country. The high diversity observed in Ecuadorian samples is closer to Brazilian and Venezuelan isolates, but lower than reported in other endemic regions. In addition, departure from neutrality was observed in Ecuadorian pvama1. Polymorphisms for pvdbpII and pvama1 were associated to B-cell epitopes.

Conclusions: pvdbpII and pvama1 genetic diversity found in Ecuadorian P. vivax was very similar to that encountered in other malaria endemic countries with varying transmission levels and segregated by geographic region. The highest diversity of P. vivax invasion genes in Ecuador was found in the Amazonian region. Although selection appeared to have small effect on pvdbpII and pvrbp1a-2, pvama1 was influenced by significant balancing selection.

Citing Articles

High-throughput genotyping of Plasmodium vivax in the Peruvian Amazon via molecular inversion probes.

Popkin-Hall Z, Niare K, Crudale R, Simkin A, Fola A, Sanchez J Nat Commun. 2024; 15(1):10219.

PMID: 39587110 PMC: 11589703. DOI: 10.1038/s41467-024-54731-y.

Genetic differentiation of Plasmodium vivax duffy binding protein in Ethiopia and comparison with other geographical isolates.

Abebe A, Dieng C, Dugassa S, Abera D, Shenkutie T, Assefa A Malar J. 2024; 23(1):55.

PMID: 38395885 PMC: 10885561. DOI: 10.1186/s12936-024-04887-1.

Genetic diversity of merozoite surface protein-5 (MSP-5) of Plasmodium vivax isolates from Malaria patients in Iran.

Mansouri S, Heidari A, Keshavarz H, Fallah P, Bairami A, Mahmoudi E BMC Infect Dis. 2023; 23(1):807.

PMID: 37978446 PMC: 10656958. DOI: 10.1186/s12879-023-08804-w.

References

Rajesh V, Elamaran M, Vidya S, Gowrishankar M, Kochar D, Das A . Plasmodium vivax: genetic diversity of the apical membrane antigen-1 (AMA-1) in isolates from India. Exp Parasitol. 2007; 116(3):252-6. DOI: 10.1016/j.exppara.2007.01.006. View

Chen E, Salinas N, Huang Y, Ntumngia F, Plasencia M, Gross M . Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein. Proc Natl Acad Sci U S A. 2016; 113(22):6277-82. PMC: 4896725. DOI: 10.1073/pnas.1600488113. View

Cole-Tobian J, Biasor M, King C . High complexity of Plasmodium vivax infections in Papua New Guinean children. Am J Trop Med Hyg. 2005; 73(3):626-33. View

Soares I, Barnwell J, Ferreira M, Gomes Da Cunha M, Laurino J, Castilho B . A Plasmodium vivax vaccine candidate displays limited allele polymorphism, which does not restrict recognition by antibodies. Mol Med. 1999; 5(7):459-70. PMC: 2230447. View

Gupta E, Anand G, Singh H, Chaddha K, Bharti P, Singh N . Naturally Acquired Human Antibodies Against Reticulocyte-Binding Domains of Plasmodium vivax Proteins, PvRBP2c and PvRBP1a, Exhibit Binding-Inhibitory Activity. J Infect Dis. 2017; 215(10):1558-1568. PMC: 5853946. DOI: 10.1093/infdis/jix170. View

Singh S, Hora R, Belrhali H, Chitnis C, Sharma A . Structural basis for Duffy recognition by the malaria parasite Duffy-binding-like domain. Nature. 2005; 439(7077):741-4. DOI: 10.1038/nature04443. View

Ju H, Kang J, Moon S, Bahk Y, Cho P, Sohn W . Genetic diversity and natural selection of Duffy binding protein of Plasmodium vivax Korean isolates. Acta Trop. 2012; 125(1):67-74. DOI: 10.1016/j.actatropica.2012.09.016. View

Cole-Tobian J, Cortes A, Baisor M, Kastens W, Xainli J, Bockarie M . Age-acquired immunity to a Plasmodium vivax invasion ligand, the duffy binding protein. J Infect Dis. 2002; 186(4):531-9. DOI: 10.1086/341776. View

Gupta S, Singh S, Popovici J, Roesch C, Shakri A, Guillotte-Blisnick M . Targeting a Reticulocyte Binding Protein and Duffy Binding Protein to Inhibit Reticulocyte Invasion by Plasmodium vivax. Sci Rep. 2018; 8(1):10511. PMC: 6043553. DOI: 10.1038/s41598-018-28757-4. View

10.

Yildiz Zeyrek F, Tachibana S, Yuksel F, Doni N, Palacpac N, Arisue N . Limited polymorphism of the Plasmodium vivax merozoite surface protein 1 gene in isolates from Turkey. Am J Trop Med Hyg. 2010; 83(6):1230-7. PMC: 2990036. DOI: 10.4269/ajtmh.2010.10-0353. View

11.

Meyer E, Semenya A, Okenu D, Dluzewski A, Bannister L, Barnwell J . The reticulocyte binding-like proteins of P. knowlesi locate to the micronemes of merozoites and define two new members of this invasion ligand family. Mol Biochem Parasitol. 2009; 165(2):111-21. PMC: 2752447. DOI: 10.1016/j.molbiopara.2009.01.012. View

12.

Lamarque M, Besteiro S, Papoin J, Roques M, Vulliez-Le Normand B, Morlon-Guyot J . The RON2-AMA1 interaction is a critical step in moving junction-dependent invasion by apicomplexan parasites. PLoS Pathog. 2011; 7(2):e1001276. PMC: 3037350. DOI: 10.1371/journal.ppat.1001276. View

13.

Ord R, Tami A, Sutherland C . ama1 genes of sympatric Plasmodium vivax and P. falciparum from Venezuela differ significantly in genetic diversity and recombination frequency. PLoS One. 2008; 3(10):e3366. PMC: 2559863. DOI: 10.1371/journal.pone.0003366. View

14.

Librado P, Rozas J . DnaSP v5: a software for comprehensive analysis of DNA polymorphism data. Bioinformatics. 2009; 25(11):1451-2. DOI: 10.1093/bioinformatics/btp187. View

15.

STAFFORD W, Gunder B, Harris A, HEIDRICH H, Holder A, Blackman M . A 22 kDa protein associated with the Plasmodium falciparum merozoite surface protein-1 complex. Mol Biochem Parasitol. 1996; 80(2):159-69. DOI: 10.1016/0166-6851(96)02696-5. View

16.

Egan A, Burghaus P, Druilhe P, Holder A, Riley E . Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol. 1999; 21(3):133-9. DOI: 10.1046/j.1365-3024.1999.00209.x. View

17.

Trucco C, Fernandez-Reyes D, Howell S, STAFFORD W, Grainger M, Ogun S . The merozoite surface protein 6 gene codes for a 36 kDa protein associated with the Plasmodium falciparum merozoite surface protein-1 complex. Mol Biochem Parasitol. 2001; 112(1):91-101. DOI: 10.1016/s0166-6851(00)00350-9. View

18.

Pizarro J, Vulliez-Le Normand B, Chesne-Seck M, Collins C, Withers-Martinez C, Hackett F . Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science. 2005; 308(5720):408-11. DOI: 10.1126/science.1107449. View

19.

Babaeekhou L, Zakeri S, Djadid N . Genetic mapping of the duffy binding protein (DBP) ligand domain of Plasmodium vivax from unstable malaria region in the Middle East. Am J Trop Med Hyg. 2009; 80(1):112-8. View

20.

Gentil F, Bargieri D, Leite J, Francoso K, Patricio M, Espindola N . A recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titres in mice. Vaccine. 2010; 28(38):6183-90. DOI: 10.1016/j.vaccine.2010.07.017. View